Key Oncology Takeaways from ESMO 2024
The Lumanity Podcast
During this episode, Lumanity experts Rob Rawlinson and Kate Goacher discuss insights and takeaways from their recent attendance at the 2024 European Society for Medical Oncology (ESMO) conference. Their conversation covers a variety of topics, including: The importance of the patient and including the patient voice in drug development The way that Artificial Intelligence (AI) could impact and innovate cancer care Insights on a selection of early-phase extensive-stage small-cell lung cancer (ES-SCLC) assets
info_outline
Embracing the Pediatric Voice from Childhood Through Young Adulthood: Elevated Insights that Fuel Your Brands' Needs
The Lumanity Podcast
In this episode, we talk about the concerns, misconceptions, and the value of engaging directly with and including the pediatric voice in market research
info_outline
Communications Testing Research: Unlock the Power of Behaviour Change
The Lumanity Podcast
In our latest Lumanity bitesize podcast, we explore how to avoid the common challenges and pitfalls encountered in communication testing research, and share best practices in applying a behavioural science lens to bring about stakeholder behaviour change. Our discussion includes: The importance of evaluating concepts using the right criteria Generating maximum impact using clear and simple ads that cut through the noise Being vigilant that the insights being used are robust and precise - and ultimately fuel better campaign decisions The importance of engaging with the target audience...
info_outline
Supporting Rare Disease Communities
The Lumanity Podcast
In this special podcast episode in honor of Rare Disease Day 2024, Angela Wheeler, President of Insight at Lumanity and Dr. Karin Hoelzer, Director of Policy and Regulatory Affairs at the National Organization for Rare Disorders (NORD), discuss opportunities for pharmaceutical companies to work with and support rare disease communities. Learn how NORD is strengthening collaboration between pharmaceutical companies and rare disease communities, and examples of the positive impact that can be made when pharmaceutical companies, organizations like NORD, and patient advocates join together. ...
info_outline
Making Social Media Listening Insights Count: Live or Let Die
The Lumanity Podcast
In this podcast episode, we explore the rich potential of social media listening (SML) insights, and how, when interpreted and acted on, they can have a significant impact on commercial decision-making. Hear from Lumanity experts as they bring SML to life using several real world examples. Topics include: How the agility, flexibility and insights from SML research are being harnessed to help improve commercial decisions How SML best complements traditional research and data The value of SML in reaching conversation leaders, HCPs and patient advocates The value for detecting commonalities and...
info_outline
Ensuring the Responsible and Meaningful Use of Generative AI in Healthcare Market Research
The Lumanity Podcast
In this podcast episode, we explore the fascinating world of artificial intelligence and its impact on the healthcare industry, as well as the ever evolving realm of research and its potentially transformative power on decision making. Hear from Lumanity experts Damian Eade, Head of Digital Insights and Analytics, Gemma Spickernell, Director of Behavioral Science, and Andrew Wood, Head of Behavioral Science as they discuss how to navigate the balance between the benefits of AI while ensuring accuracy and integrity in research. This thought-provoking conversation considers the potential of...
info_outline
The Importance of RWE Strategy Planning
The Lumanity Podcast
There are incredible synergies with joint HEOR and Real World Evidence (RWE) projects, but there are also unique challenges. In this podcast episode, The Importance of RWE Strategy Planning, Ann-Marie Chapman, Nikita Jeswani, Meena Venkatachalam, and Alex Thorel discuss the use cases and planning for RWE, identifying appropriate RWE, and RWE trends. Listen to this podcast to learn: · Key considerations, steps, and recommendations in identifying appropriate data sources · Where RWD and...
info_outline
Launch Excellence Alchemy: Managing Strategic Risk
The Lumanity Podcast
Strategic risk is often overlooked within the pharmaceutical industry. There’s a perception that someone else is picking up the risk ball. Or there is more of a focus on internal risks, with little thought to the larger external factors that can have a significant impact on your launch. We see common risks arise from competitor launches, multi-indication launches, and supply chain issues. Unmitigated risks can lead to costly delays. So, what can you do to identify the risks for your asset launch and successfully mitigate them? In our latest Launch Excellence Alchemy podcast, our team of...
info_outline
Launch Excellence Alchemy: Mindset, Leadership, and the Value of a 'Third Voice'
The Lumanity Podcast
We know that effective collaboration across cross-functional and global/local launch teams is one of the critical elements to launch success – but teams often struggle to develop the right behaviors that foster a truly collaborative culture. Leadership styles too play a vital role, with research directing us away from ‘leading from the front’, towards a model that champions interdependent leadership and shared accountability. In the second episode of our series on launch excellence, we explore how: Heroic leadership styles can hinder collaboration when launching a product Looking at...
info_outline
Possible Implications of the Inflation Reduction Act for Oncology Products and Stakeholders
The Lumanity Podcast
In this episode, Dr. Nancy McGee and Rob Rawlinson discuss potential implications of the Inflation Reduction Act (IRA) legislation that was passed in the U.S. in 2022. This episode covers: An overview of the IRA in relation to healthcare The potential impacts for oncology patients, manufacturers, and oncologists The impact of the legislation outside of the U.S. Speakers: Nancy McGee, JD, MPH, DrPH, Senior Vice President, Health Policy & Public Payers, Lumanity Rob Rawlinson, Director, Oncology Insights Lead, Lumanity ©2023 Lumanity Inc.
info_outlineDuring the launch of a new medicine, there is so much focus on the intellectual strategy, that it's easy to sideline thoughts about "How are we going to collaborate as a team to make this happen?"
But statistics show that strong teamwork can deliver up to 3x more shareholder value. Investing time in good cross-functional collaboration is not just a nice-to-have, it's a must-have for successful launch teams.
In the first episode of our series on launch excellence, we explore the following:
- How strong internal collaboration delivers optimal launch outcomes
- Why a team ‘contract’ can transform a launch team’s ways of workings
- The role leadership plays in driving cross-functional launch alignment and how much influence it delivers to success
Join Lumanity staff Tracey Barnes, Vice President of Launch Excellence, and Kirsty Tait, a leading Launch Excellence Consultant, as they untangle the intricacies of cross-functional collaboration to share what good launch teams are doing that sets them apart from the rest.